Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XIN5789
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
01
Overview
XIN5789 is an early-stage small molecule drug candidate originally developed by XinThera, Inc., a biotechnology company that was acquired by Gilead Sciences in May 2023. XinThera specialized in the discovery of highly selective small molecules targeting oncology and inflammation. While the company's lead assets included a PARP1 inhibitor (XIN-018) and an MK2 inhibitor (XIN-109), XIN5789 was part of the broader pipeline acquired by Gilead. Specific details regarding its biological target, mechanism of action, and primary clinical indications remain undisclosed, though it is categorized within XinThera's focus areas of neoplasms, immune system diseases, and nervous system diseases.
Beyond the preview
Go deeper on XIN5789.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XIN5789.